John Francis Cogan Sells 5,833 Shares of Gilead Sciences, Inc. (GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 5,833 shares of the stock in a transaction on Monday, March 12th. The shares were sold at an average price of $80.93, for a total value of $472,064.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.72 on Wednesday. The stock has a market capitalization of $106,186.01, a PE ratio of 23.48, a PEG ratio of -1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.70 EPS. sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in the company. Welch Investments LLC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $133,000. Certified Advisory Corp bought a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $144,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $147,000. Institutional investors and hedge funds own 77.96% of the company’s stock.
GILD has been the subject of a number of recent analyst reports. Leerink Swann restated a “market perform” rating and set a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Finally, Wells Fargo & Co upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $79.02 to $96.00 in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $88.61.
COPYRIGHT VIOLATION NOTICE: “John Francis Cogan Sells 5,833 Shares of Gilead Sciences, Inc. (GILD) Stock” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/14/john-francis-cogan-sells-5833-shares-of-gilead-sciences-inc-gild-stock.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.